CSPC Pharmaceutical Group Ltd. has received clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials of antibody-drug conjugates (ADCs) SYS-6005 and SYS-6043.
Iomx Therapeutics AG has submitted a clinical trial application (CTA) for IOMX‑0675, a dual‑targeting, fully human antibody designed to address the key immune-regulatory LILR receptor family expressed on myeloid and lymphoid immune cells.
Inceptor Bio LLC and Shenzhen Grit Biotechnology Co. Ltd. have established a strategic partnership to advance IB-T101, a CAR T therapy targeting solid tumors.
Tigatx Inc. has been awarded up to $33.5 million in funding by the Advanced Research Projects Agency for Health and a 2-year $2 million Direct to Phase II Small Business Innovation Research grant from the National Cancer Institute.
B7H3 is a pan-cancer antigen considered a promising target for immunotherapy. However, targeting B7H3 using bispecific T-cell engagers (BiTEs) presents the problem of systemic toxicity.
Cathepsin G (CTSG) is overexpressed and aberrantly localized for antigen presentation on acute myeloid leukemia blasts and stem cells compared to normal hematopoietic progenitors. Earlier this year, Crossbow Therapeutics Inc. announced the nomination of its first development candidate, CBX-250, a TCR-mimetic (TCRm) bispecific T-cell engager (TCE) antibody targeting a CTSG peptide-human leukocyte antigen (pHLA) complex and CD3.
The lack of acute myeloid leukemia-specific antigens is one of the challenges for targeted immunotherapy together with on-target off-tumor toxicities due to the expression of the target in normal myeloid cells. A subset of T cells – Vδ2 T-cells – which represent ~5% of the T-cell population in healthy donors, are seen as part of emerging immunotherapeutic strategies.
Claudin 18.2 (CLDN18.2) is a member of the claudin family and is overexpressed in gastric, gastroesophageal junction and pancreatic cancer, among others. Researchers from Elevation Oncology Inc. recently presented preclinical efficacy data on the combination of EO-3021, an antibody-drug conjugate (ADC) targeting CLDN18.2, with VEGFR-2 or PD-1 inhibitors in models of gastric adenocarcinoma.
Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s Office of Autoimmune Disease Research and Office of Research in Women’s Health earlier this month. Cancer, that line of reasoning goes, arises when the immune system is not good enough at recognizing harmful autoantigens. Autoimmunity arises when it is hypervigilant, mistaking harmless autoantigens for problematic ones and going on the attack.
Elevation Oncology Inc. has nominated EO-1022 as its HER3 antibody-drug conjugate (ADC) development candidate for the treatment of solid tumors that express HER3.
RSS
